Skip to content

{ Category Archives: } Biotech (General)

The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense’s product for ALS patients.

HERZLIYA, Israel, Feb. 6, 2020 /PRNewswire/ — NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced today the initiation of two clinical studies to evaluate the benefit of PrimeC for ALS patients. A Phase IIa study is being conducted in Israel at Tel-Aviv Sourasky Medical Center (TASMC), by Prof. Vivian Drory. A similar…

11 drugs likely to become blockbusters

The 11 drugs Clarivate expects to become blockbusters by 2024: Rimegepant (Biohaven Pharmaceutical) — designed to treat migraines. OMG-157 (Novartis) — designed to treat multiple sclerosis. Ozanimod (Celgene) — designed to treat multiple sclerosis. Vadadustat (Akebia Therapeutics/Mitsubishi Tanabe Pharma America/ Otsuka Pharmaceutical) — designed to treat anemia caused by chronic kidney disease. Valrox (BioMarin Pharmaceutical)…

Collaboration Formed to Develop New Radiochemicals for Diagnosing, Treating Brain Diseases

A collaborative effort between Fuzionaire Diagnostics, McGill University and The Neuro (Montreal Neurological Institute-Hospital) will foster the development of a new class of radioactive molecules — called radiochemicals — for the diagnosis and treatment of neurodegenerative diseases, including Parkinson’s disease. Radiochemicals are compounds prepared with radioactive elements that are used for medical applications, such as tracers in positron emission tomography (PET) scans. PET scan…

Major cancer institute sued by its own researchers over ‘tapering’ funding

Alleging that a leading cancer funder is slashing their support in an “unethical and reckless” way, six prominent cancer researchers at the University of California, San Diego (UCSD), have filed a lawsuit to compel it to continue its current level of support. The suit, filed quietly in November 2019 and amended last week, contends that the…

Oligomerix to Present at BIO CEO & Investor Conference, TAU2020 Global Conference

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announces that the company will be presenting at two conferences this month. James Moe, Ph.D., MBA, President and CEO of Oligomerix, will provide a company overview at the 2020 BIO CEO &…

Targeting Amyloid Oligomers for Alzheimer’s Research

Alzheimer’s disease is one of the most frightening diseases people can face. The deterioration of memory and comprehension and, ultimately death, is a terrifying concept. And little headway has been made in developing a treatment for this disease. But that could be changing. Biogen is likely on the road to having aducanumab approved as a…

BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference

NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO and President, will provide an update of the Company’s ALS and MS trials and company growth strategy at The BIO CEO & Investor Conference, being held…

Salk scientists link rapid brain growth in autism to DNA damage

LA JOLLA–(January 30, 2020) Researchers at the Salk Institute have discovered a unique pattern of DNA damage that arises in brain cells derived from individuals with a macrocephalic form of autism spectrum disorder (ASD). The observation, published in the journal Cell Stem Cell, helps explain what might go awry in the brain during cell division and…

BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent titled ‘Methods of Generating Mesenchymal Stem Cells which secrete Neurotrophic Factors’. Allowed claims cover the method for manufacturing…

Bausch Health Companies (BHC) Receives a Buy from Barclays

In a report issued on January 24, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research Report), with a price target of $33.00. The company’s shares closed last Monday at $28.40. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 16.6% and a 70.0% success rate. Prasad covers the Healthcare sector, focusing on stocks…